Shares of Genmab A/S have moved 2.1% today, and are now trading at a price of $21.01. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 724,162 compared to the stock's average volume of 1,292,411.
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Based in Copenhagen, Denmark the company has 2,635 full time employees and a market cap of $13,418,457,088.
The company is now trading -42.53% away from its average analyst target price of $36.56 per share. The 9 analysts following the stock have set target prices ranging from $23.5 to $50.0, and on average give Genmab A/S a rating of buy.
Over the last 12 months GMAB shares have declined by -35.4%, which represents a difference of -61.9% when compared to the S&P 500. The stock's 52 week high is $32.88 per share and its 52 week low is $19.85. With its net margins declining an average -6.9% over the last 6 years, Genmab A/S declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 5,402,000 | 1,408,000 | 26 | 0.0 |
| 2023 | 16,474,000 | 4,352,000 | 26 | -31.58 |
| 2022 | 14,505,000 | 5,452,000 | 38 | 8.57 |
| 2021 | 8,417,000 | 2,957,000 | 35 | -25.53 |
| 2020 | 10,111,000 | 4,758,000 | 47 | 17.5 |
| 2019 | 5,366,000 | 2,166,000 | 40 |
